

Genzyme Corporation (GENZ)

Analyst Schedule

(Unaudited, amounts in thousands, except percentage amounts)

	Q4-07	Q1-08	Q2-08	Q3-08	Q4-08	Q4-08 vs. Q4-07 % B/(W)	FY 2006	FY 2007	FY 2008
Total revenues:									
Genetic Diseases									
Cerezyme	\$ 300,312	\$ 304,303	\$ 319,360	\$ 309,280	\$ 306,034	2%	\$ 1,007,036	\$ 1,133,153	\$ 1,238,977
Fabrazyme	114,661	116,475	126,608	125,619	125,558	10%	359,274	424,284	494,260
Myozyme	62,496	67,324	77,222	76,663	74,967	20%	59,238	200,728	296,176
Aldurazyme	-	37,015	38,834	38,236	37,579		-	-	151,664
Other Genetic Diseases	7,289	9,772	10,437	11,367	14,039	93%	410	8,314	45,615
Total Genetic Diseases product and service revenue	484,758	534,889	572,461	561,165	558,177	15%	1,425,958	1,766,479	2,226,692
R&D Revenue	5	-	-	-	-		1,000	1,059	-
Total Genetic Diseases	484,763	534,889	572,461	561,165	558,177	15%	1,426,958	1,767,538	2,226,692
Cardiomatabolic and Renal									
Renagel and Renvela (including Sevelamer)	166,173	168,694	168,567	170,992	169,476	2%	515,119	602,670	677,729
Hectorol	29,855	29,076	30,852	33,825	34,400	15%	93,360	115,708	128,153
Subtotal	196,028	197,770	199,419	204,817	203,876	4%	608,479	718,378	805,882
Thyrogen	30,881	33,785	39,448	38,153	37,062	20%	93,687	113,587	148,448
Other Cardiomatabolic and Renal	92	251	333	573	496	>100%	-	103	1,653
Total Cardiomatabolic and Renal product and service revenue	227,001	231,806	239,200	243,543	241,434	6%	702,166	832,068	955,983
R&D revenue	102	32	85	56	27	(74%)	2,142	1,200	200
Total Cardiomatabolic and Renal	227,103	231,838	239,285	243,599	241,461	6%	704,308	833,268	956,183
Biosurgery									
Synvisc	62,685	56,142	70,927	67,513	68,512	9%	233,858	242,319	263,094
Sepra products	29,746	30,604	34,780	33,001	35,278	19%	85,338	104,318	133,663
Other Biosurgery	21,122	24,313	24,690	21,787	20,908	(1%)	67,480	74,673	91,698
Total Biosurgery product and service revenue	113,553	111,059	130,397	122,301	124,698	10%	386,676	421,310	488,455
R&D revenue	666	603	818	661	563	(15%)	893	5,337	2,645
Total Biosurgery	114,219	111,662	131,215	122,962	125,261	10%	387,569	426,647	491,100
Hematologic Oncology									
Total Hematologic Oncology product and service revenue	21,628	22,691	26,443	26,328	27,437	27%	49,179	69,927	102,899
R&D revenue	1,216	1,189	1,903	2,292	9,055	>100%	8,097	7,006	14,439
Total Hematologic Oncology	22,844	23,880	28,346	28,620	36,492	60%	57,276	76,933	117,338
Other									
Genetic/Diagnostics product and service revenue	108,872	114,748	116,863	121,163	124,840	15%	355,866	410,917	477,614
Transplant product and service revenue	47,424	45,930	47,763	47,784	50,723	7%	155,966	174,826	192,200
Other product and service revenue	27,981	31,009	29,296	28,598	30,252	8%	93,716	108,577	119,155
Total Other product and service revenue	184,277	191,687	193,922	197,545	205,815	12%	605,548	694,320	788,969
R&D revenue	3,552	6,105	5,905	6,393	6,354	79%	5,354	14,813	24,757
Total Other	187,829	197,792	199,827	203,938	212,169	13%	610,902	709,133	813,726
Total revenues	\$ 1,036,758	\$ 1,100,061	\$ 1,171,134	\$ 1,160,284	\$ 1,173,560	13%	\$ 3,187,013	\$ 3,813,519	\$ 4,605,039

All amounts herein are presented in accordance with GAAP and are provided for quantitative analysis only and should be read in conjunction with the text of the Earnings Release and our audited financial statements filed with the Securities and Exchange Commission. Please refer to our Form 10-Q's and Form 10-K's for an in-depth discussion and analysis of our results of operations and financial position and for detailed information regarding specific material transactions in a particular period.